Amicus Therapeutics (Amicus Therapeutics) EBIT per Share : $-0.34 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics EBIT per Share?

Amicus Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was $-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.34.

During the past 3 years, the average EBIT per Share Growth Rate was 35.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 28.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Amicus Therapeutics's EBIT per Share or its related term are showing as below:

FOLD' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -65.1 Med: 14.4 Max: 84.1
Current: 35.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Amicus Therapeutics was 84.10% per year. The lowest was -65.10% per year. And the median was 14.40% per year.

FOLD's 3-Year EBIT Growth Rate is ranked better than
85.31% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs FOLD: 35.80

Amicus Therapeutics's EBIT for the three months ended in Dec. 2023 was $-18.8 Mil.

Amicus Therapeutics EBIT per Share Historical Data

The historical data trend for Amicus Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics EBIT per Share Chart

Amicus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.40

-0.97

-0.77

-0.71

-0.34

Amicus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.20	-0.14	-0.10	-0.04	-0.06

Amicus Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Amicus Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-99.952	/	295.165
=	-0.34

Amicus Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.833	/	300.716
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34

Amicus Therapeutics (NAS:FOLD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Amicus Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics (Amicus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Executives

John F Crowley	director, officer: Executive Chairman	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark	officer: Chief People Officer	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout	officer: Principal Accounting Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg	officer: General Counsel & Corp. Secy	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli	officer: VP, Program Management	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r.	officer: Chief Financial Officer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab	director	1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi	officer: Chief Financial Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman	director	13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do	officer: Sr Vice President Discovery	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly	director	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth	officer: Chief Medical Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512